Tenpoint and Visus Therapeutics Collaborate on Innovative Ophthalmic Medicines

Tenpoint Therapeutics, Limited and Visus Therapeutics, Inc. recently finalized a merger, creating a new enterprise poised to impact the field of ophthalmic therapies, particularly focusing on the aging eye. This merger combines a promising late-stage eye drop for presbyopia, BRIMOCHOL™ PF, with a variety of innovative therapeutic developments. BRIMOCHOL™ PF is anticipated to submit a New Drug Application (NDA) in the first half of 2025.

The merger is backed by a group of institutional investors dedicated to propelling BRIMOCHOL™ PF towards market approval and making it accessible globally. They also aim to further develop Tenpoint’s pipeline into clinical stages.

Tenpoint Therapeutics is advancing three main programs targeting eye rejuvenation:

1. **BRIMOCHOL™ PF**: This is a unique, patent-protected eye drop designed to correct presbyopia, an age-related vision condition. It combines carbachol, a potent miotic, with brimonidine, an alpha2-agonist. This combination not only enhances efficacy and prolongs duration but also reduces ocular redness due to brimonidine’s vasoconstrictive properties. This offers a potentially superior solution for presbyopia.

2. **TPT-161**: A novel small molecule aimed at reversing cataract formation in older adults.

3. **TPT-005**: A cell therapy focused on replacing retinal pigment epithelium (RPE) cells to address geographic atrophy.

To support these programs, Tenpoint is preparing for a Crossover financing round, involving insider participation to fund the completion of BRIMOCHOL™ PF’s clinical trials and prepare for its U.S. market launch in the first half of 2026.

With the merger, Henric Bjarke has been appointed as Chief Executive Officer. His extensive experience in the biopharmaceutical industry, particularly in ophthalmology, will guide the newly merged company. Bjarke has held significant roles in various successful companies, contributing to his expertise in developing and launching innovative ophthalmic products.

He expressed enthusiasm about the merger, noting the potential of combining resources to launch groundbreaking therapies, starting with BRIMOCHOL™ PF for presbyopia. The merger’s goal is to lead the market with first-class ophthalmic medicines.

David Guyer, MD, Chairman of the Board, emphasized the merger as a pivotal step for both companies. He is eager to work with the new leadership team to bring BRIMOCHOL™ PF to market and push forward products addressing unmet needs in ocular diseases.

Tenpoint Therapeutics is a global biotech firm in the clinical stage, developing novel treatments to enhance vision in aging eyes. Their innovative pipeline targets significant ophthalmic conditions such as presbyopia, cataracts, and geographic atrophy. BRIMOCHOL™ PF, the company’s leading asset, aims to tackle the near vision loss associated with presbyopia, affecting around 2 billion people worldwide. Having completed its first Phase 3 trial, BRIMOCHOL™ PF is on track to finish another pivotal study by 2025 and is set for a 2026 launch.

With a leadership team experienced in securing approvals and commercializing major drugs, Tenpoint is supported by investors such as AdBio Partners, British Patient Capital, and others. This merger marks a significant step in offering innovative solutions for age-related eye conditions.